Senores Pharmaceuticals has announced significant changes in its senior management team. The Board of Directors has approved the appointment of Mr. Jatin Gajjar as Chief Technology Officer, categorising him as Senior Management Personnel (SMP). This decision was made based on the recommendation of the Nomination and Remuneration Committee and was approved through a circular resolution passed on March 17, 2026.
Mr. Jatin Gajjar brings over three decades of leadership experience in pharmaceutical technology, manufacturing operations, and product development. His expertise lies in complex formulations, regulatory compliance, and process optimisation. He has played a pivotal role in advancing complex generics, injectable formulations, and novel drug delivery technologies, enabling regulatory approvals and commercialisation across key markets. At Senores, he will provide strategic leadership across R&D, manufacturing, and regulatory affairs, aligning technology with business goals and fostering a culture of innovation and scientific excellence. Previously, Mr. Gajjar held leadership roles at global pharmaceutical organisations, including Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma, and Aventis Pharma.
In a concurrent development, Mr. Manohar Lalge, President of Research and Development, has tendered his resignation, effective from the close of business hours on March 17, 2026. Mr. Lalge’s departure marks the end of his tenure as SMP at Senores Pharmaceuticals.
The company has stated that the terms and conditions of Mr. Gajjar’s appointment are detailed in his letter of appointment. The resignation of Mr. Lalge and the appointment of Mr. Gajjar are in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
These changes are part of Senores Pharmaceuticals’ ongoing efforts to strengthen its leadership team and enhance its operational capabilities. The company has uploaded this information on its website for public access.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).
This article is written by Yash Agarwal and reviewed by Aman Shukla before publication.